Siren Biotechnology blends two revolutionary therapeutic technologies into one for a novel approach to treating cancer.AAV gene therapy and cytokine immunotherapy are two revolutionary treatment approaches that Siren Biotechnology has combined into a single, redesigned modality. This approach overcomes significant obstacles and entirely transforms how tumor cells are eliminated and anti-tumor immunity is stimulated.
Wyndly offers personalized prescription treatment and online care. With the help of clinically tested therapies, the company's expert providers collaborate with the clients to create a personalized treatment plan that offers long-term allergy relief.
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. Kernal won three awards from Amgen and NASA. With roots at MIT, Harvard and Big Pharma, the team previously built a successful Biotech company and has deep expertise in mRNA space.
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Klivo is a health technology company that operates a patient management platform designed to support individuals with chronic conditions in leading healthier lives. The platform enables real-time monitoring of health conditions and facilitates the transmission of blood glucose data. Additionally, it provides users with answers to questions related to clinical conditions, nutrition, and other relevant topics. By equipping healthcare professionals with essential data and insights, Klivo aims to enhance clinical outcomes for patients managing chronic illnesses.
Teiko.bio is an immune profiling platform that enables clinicians to make informed decisions around patient response. The company was founded in 2020 and is based in Salt Lake City, Utah.
OxCan is a startup that uses machine learning and liquid biopsy for early lung cancer detection.
Axonis Therapeutics is a neuro-focused biotechnology company developing medicines targeting KCC2, the critical mediator of inhibition within the brain, by translating breakthrough discoveries from Boston Children’s Hospital, Harvard, and Laval University. It develops a proprietary neuron-specific K-Cl cotransporter (KCC2) discovery engine to improve the lives of people suffering from neurological disorders by fine-tuning inhibition to treat conditions such as epilepsy, pain, and other central nervous system pathologies.
Glyphic Biotechnologies is a biotechnology company that develops a protein sequencing platform. While DNA can reveal biological insights, proteins provide the actual insights into the functions of our bodies. The company is in the process of developing a pioneering, next-generation protein sequencing platform that will empower researchers to acquire unprecedented insights into both biology and diseases.
Foresight Diagnostics develops a novel liquid biopsy test for the measurement of minimal residual disease to aid in patient management. They garnered significant partnering interest from multiple pharmaceutical companies in oncology.
Catena Biosciences is a biotechnology company that offers protein conjugation, building biologic structures, and medical research.
ULab develops a breakthrough software technology for digital dental treatment planning. It’s proprietary architecture and fully automated features enable orthodontists, for the first time, to create chairside treatment plans in less than 5 minutes.
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety. It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacy and safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Kit specializes in at-home health and lab testing solutions that enable businesses and organizations to offer a safe and convenient alternative to traditional doctor and laboratory visits. The company's comprehensive testing kits are designed to make preventative health testing accessible across various industries, allowing customers to manage their health from the comfort of their homes. By providing reliable and easy-to-use testing options, Kit aims to enhance the accessibility of health services for individuals and organizations alike.
R-Zero offers smart building technology that delivers real-time insights on optimizing indoor spaces to improve workforce productivity, predict real estate needs, and create operational efficiencies, including reducing energy costs. R-Zero’s smart building solutions include IAQ and comfort monitoring, high-efficiency HVAC filtration, space utilization sensors, occupancy-based building controls, and real estate performance analytics. R-Zero’s connected platform is easy-to-use, secure, and scalable, enabling owners, operators, and their tenants, to prepare their buildings for tomorrow's challenges.
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Fluent Biosciences is a life science "single cell" technology company that offers molecular analysis of cells without the use of complex microfluidic instrumentation. The company’s proprietary platform, Pre-Templated Instant Partitions (PIPseqTM), provides instantaneous self-assembly of individual cells or molecules into millions of uniform partitions for sensitive, unbiased preparation of proteins and nucleic acids for sequencing applications. Fluent's technology expands accessibility of single cell, molecule, or protein analysis to every laboratory, enabling broader market access across all researchers in biotech, pharma, and academic centers.
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.
At Gali Health, we are on a mission to make sure nobody ever feels isolated, lost or powerless in the face of existing or potential disease. We are working to advance consumer-powered healthcare by crowdsourcing personal health data and medically-validated insights, applying AI to process them and providing highly personalized informational support on the medical, lifestyle and psychological aspects of living with chronic disease. Our mobile personal health assistant named Gali relies on collective intelligence to help people with chronic conditions proactively manage their health.
DermBiont is a biotech company that develops skin microbiome therapeutics to treat and prevent skin diseases. It is at the intersection of two highly active sectors: dermatology and the microbiome. They harness naturally occurring microbes on the human skin that have evolved over hundreds of thousands of years to compete with pathogenic microbes (fungi, bacteria, viruses, etc.). The company was founded in 2017 and is headquartered in Boston, Massachusetts with a satellite office in Emeryville, California.
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.
Wild Earth is a technology startup that specializes in developing protein pet foods. It is dedicated to reinventing pet food with science to offer healthier foods for pets that are better for the environment and more humane than conventional products. The company was founded in 2017 and is headquartered in Berkeley, California.
BillionToOne is a precision diagnostics company that quantifies biology to create molecular diagnostics accurate, efficient, and accessible for all. The company's patent-pending molecular counter platform is a technology platform that can accurately count the DNA molecules to the single-count level. BillionToOne's mission is to make pre-natal testing safe and affordable for every expecting mother. Its novel technology can detect even single-gene disorders such as thalassemia through a simple blood test. They are replacing amniocentesis, an invasive and risky procedure that has a high miscarriage risk, with a safe and affordable blood test, starting in developing countries. BillionToOne was founded in 2016 and is headquartered in Menlo Park, California.
Qulab redesigns the procedure of research and development in the chemical and pharmaceutical industries by incorporating automation and computing technology. They are using computational chemistry, artificial intelligence, and quantum computing to automate the design of small molecule medications.
ULab develops a breakthrough software technology for digital dental treatment planning. It’s proprietary architecture and fully automated features enable orthodontists, for the first time, to create chairside treatment plans in less than 5 minutes.
Curai is a virtual care company that uses artificial intelligence to provide chat-based primary care at a lower cost. It aims to make affordable, high-quality primary care accessible to everyone on the planet, whenever they want it. Founded by Neal Khosla and Xavier Amatriain in 2017, Curai Health offers chat-based primary care that combines clinicians with the industry's most advanced AI to create a learning healthcare system that increasingly slashes the cost of delivering high-quality care. Headquartered in Palo Alto, Curai Health is available directly to consumers or through enterprise partnerships.
evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.
Alveo Technologies is changing the world by applying cutting edge advances in sensing, microfluidics, and bioassays to create the next-generation of disease and personal care diagnostic devices.Their innovative products connect and empower consumers, healthcare professionals and treatment providers with the ability to know sooner, act faster, and make better-informed decisions. Advanced diagnostics clear the path to more personalized medicine and better outcomes.
Singular Bio's technology provides single molecule analysis of a patient's DNA, giving exquisite sensitivity for detecting many common conditions. The company's mission is to expand access to fundamental healthcare information by making advanced genetic tests available to everyone.
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier. The company was founded in 2016 and is based in San Francisco, California.
ULab develops a breakthrough software technology for digital dental treatment planning. It’s proprietary architecture and fully automated features enable orthodontists, for the first time, to create chairside treatment plans in less than 5 minutes.
Manus Bio Inc. recreates plant processes in microorganisms to produce natural ingredients through fermentation. The company’s microbial platform converts sugar sources into ingredients with applications, such as flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. It merges metabolic engineering, protein engineering, and systems biology technologies to generate microbes that produce various plant-based ingredients. The company has a strategic partnership with BBGI Public Company Limited. Manus Bio Inc. was formerly known as Manus Biosynthesis, Inc. and changed its name to Manus Bio Inc. in June 2018. The company was founded in 2011 and is based in Cambridge, Massachusetts. It has manufacturing facilities in Cambridge, Massachusetts; and Augusta, Georgia.
Omada Health is a digital care company that offers innovative and clinically effective digital health programs to empower individuals to engage in their health and lead healthier lives. The program is personalized to meet each participant’s unique needs as they evolve, ranging from diabetes prevention, type 2 diabetes management, hypertension, behavioral health, and musculoskeletal issues. Omada combines professional health coaching, connected health devices, real-time data, and personalized feedback to deliver clinically meaningful results. The company is the largest CDC-recognized provider of the National Diabetes Prevention Program.
Lemonaid Health focuses on changing the patient experience and improving and optimizing clinical care through advancements in machine learning and AI. It leverages evidence-based guidelines and the most up-to-date clinical protocols to offer a service direct to consumers for less than typical co-pays. It was founded in 2013 and is headquartered in San Francisco, California.
Rocket Pharmaceuticals is a biotechnology company that is working to develop first-in-class gene therapy treatments for rare and undertreated diseases. The Company's lead program is a lentiviral-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult-to-treat genetic disease that causes bone marrow failure and, in the worst-case scenario, cancer. Additional bone marrow-derived disorders are being studied in preclinical trials, including Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-1 (LAD-1), and Infantile Malignant Osteopetrosis. In addition, the company is working on an AAV-based gene therapy program for an unnamed rare pediatric disease.
Multerra Bio is a business enterprise that develops the research program in various clinical treatments.
Pillo Health provides HIPAA compliant tools for caregivers and health organizations to deliver better care to loved ones and patients living at home. The company's care delivery platform is centered on an intelligent healthcare assistant called Pillo. In addition to managing medications, Pillo can provide patients at home with health and wellness information, can proactively deliver digital care plans into the home, and can connect the home to care teams via smart notifications and video calling. The company also offers an SDK for partner organizations to create their own unique skills for Pillo by leveraging the company's proprietary in home voice first device.